Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence.

Weber MA, Mahfoud F, Schmieder RE, Kandzari DE, Tsioufis KP, Townsend RR, Kario K, Böhm M, Sharp ASP, Davies JE, Osborn JW, Fink GD, Euler DE, Cohen DL, Schlaich MP, Esler MD.

JACC Cardiovasc Interv. 2019 Jun 24;12(12):1095-1105. doi: 10.1016/j.jcin.2019.02.050. Review.

PMID:
31221299
2.

Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review.

Kiuchi MG, Esler MD, Fink GD, Osborn JW, Banek CT, Böhm M, Denton KM, DiBona GF, Everett TH 4th, Grassi G, Katholi RE, Knuepfer MM, Kopp UC, Lefer DJ, Lohmeier TE, May CN, Mahfoud F, Paton JFR, Schmieder RE, Pellegrino PR, Sharabi Y, Schlaich MP.

J Am Coll Cardiol. 2019 Jun 18;73(23):3006-3017. doi: 10.1016/j.jacc.2019.04.015. Review.

PMID:
31196459
3.

Obesity-Associated Organ Damage and Sympathetic Nervous Activity.

Lambert EA, Esler MD, Schlaich MP, Dixon J, Eikelis N, Lambert GW.

Hypertension. 2019 Jun;73(6):1150-1159. doi: 10.1161/HYPERTENSIONAHA.118.11676. No abstract available.

PMID:
31067200
4.

Successful Renal Denervation Decreases the Platelet Activation Status in Hypertensive Patients.

Zaldivia MTK, Hering D, Marusic P, Sata Y, Lee R, Esler MD, Htun NM, Duval J, Hammond L, Flierl U, Wang X, Drummond GR, Walton A, Gardiner EE, Andrews RK, Schlaich MP, Peter K.

Cardiovasc Res. 2019 Feb 4. doi: 10.1093/cvr/cvz033. [Epub ahead of print]

PMID:
30715163
5.

Fine tuning renal denervation.

Esler MD.

J Hypertens. 2018 Dec;36(12):2312-2313. doi: 10.1097/HJH.0000000000001883. No abstract available.

PMID:
30379785
6.

Renal Denervation-Ready for Prime Time!? The Steep SPYRAL Stairs to RADIANCE in Hypertension Treatment.

Schlaich MP, Kiuchi MG, Esler MD.

Hypertension. 2018 Aug;72(2):287-290. doi: 10.1161/HYPERTENSIONAHA.118.11532. Epub 2018 Jun 25. No abstract available.

PMID:
29941510
7.

Reply.

Sata Y, Head GA, Esler MD, Schlaich MP.

J Hypertens. 2018 Jul;36(7):1606-1607. doi: 10.1097/HJH.0000000000001765. No abstract available.

PMID:
29847455
8.

Take a blood pressure pill or undergo renal denervation?

Kjeldsen SE, Esler MD.

Lancet. 2018 Jun 9;391(10137):2298-2300. doi: 10.1016/S0140-6736(18)31126-7. Epub 2018 May 23. No abstract available.

PMID:
29803587
9.

A polymorphism in the noradrenaline transporter gene is associated with increased blood pressure in patients with resistant hypertension.

Eikelis N, Marques FZ, Hering D, Marusic P, Head GA, Walton AS, Lambert EA, Esler MD, Sari CI, Schlaich MP, Lambert GW.

J Hypertens. 2018 Jul;36(7):1571-1577. doi: 10.1097/HJH.0000000000001736.

PMID:
29677047
10.

Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial.

Stoiber L, Mahfoud F, Zamani SM, Lapinskas T, Böhm M, Ewen S, Kulenthiran S, Schlaich MP, Esler MD, Hammer T, Stensæth KH, Pieske B, Dreysse S, Fleck E, Kühne T, Kelm M, Stawowy P, Kelle S.

Clin Res Cardiol. 2018 Aug;107(8):642-652. doi: 10.1007/s00392-018-1229-z. Epub 2018 Mar 8.

11.

Ambulatory arterial stiffness index as a predictor of blood pressure response to renal denervation.

Sata Y, Hering D, Head GA, Walton AS, Peter K, Marusic P, Duval J, Lee R, Hammond LJ, Lambert EA, Lambert GW, Esler MD, Schlaich MP.

J Hypertens. 2018 Jun;36(6):1414-1422. doi: 10.1097/HJH.0000000000001682.

PMID:
29465712
12.

Modulation of renal sympathetic innervation: recent insights beyond blood pressure control.

Linz D, Hohl M, Elliott AD, Lau DH, Mahfoud F, Esler MD, Sanders P, Böhm M.

Clin Auton Res. 2018 Aug;28(4):375-384. doi: 10.1007/s10286-018-0508-0. Epub 2018 Feb 10. Review.

PMID:
29429026
13.

Does sympathetic dysfunction occur before denervation in pure autonomic failure?

Guo L, Esler MD, Sari C, Phillips S, Lambert EA, Straznicky NE, Lambert GW, Corcoran SJ.

Clin Sci (Lond). 2018 Jan 2;132(1):1-16. doi: 10.1042/CS20170240. Print 2018 Jan 16.

PMID:
29162745
14.

Renal Denervation After the SPYRAL HTN-OFF MED Trial: Putting a Complex Study Into Context.

Schlaich MP, Esler MD.

Hypertension. 2017 Dec;70(6):1076-1079. doi: 10.1161/HYPERTENSIONAHA.117.10290. Epub 2017 Oct 16. No abstract available.

PMID:
29038200
15.

Predictive factors for successful renal denervation: should we use them in clinical trials?

Barber-Chamoux N, Esler MD.

Eur J Clin Invest. 2017 Nov;47(11):860-867. doi: 10.1111/eci.12792. Epub 2017 Oct 16. Review.

PMID:
28771706
16.

The Effect of Renal Denervation on Plasma Adipokine Profile in Patients with Treatment Resistant Hypertension.

Eikelis N, Hering D, Marusic P, Duval J, Hammond LJ, Walton AS, Lambert EA, Esler MD, Lambert GW, Schlaich MP.

Front Physiol. 2017 May 30;8:369. doi: 10.3389/fphys.2017.00369. eCollection 2017.

17.

NET silencing by let-7i in postural tachycardia syndrome.

Khan AW, Ziemann M, Corcoran SJ, K N H, Okabe J, Rafehi H, Maxwell SS, Esler MD, El-Osta A.

JCI Insight. 2017 Mar 23;2(6):e90183. doi: 10.1172/jci.insight.90183.

18.

Greater sympathoadrenal activation with longer preventilation intervals after immediate cord clamping increases hemodynamic lability at birth in preterm lambs.

Smolich JJ, Kenna KR, Esler MD, Phillips SE, Lambert GW.

Am J Physiol Regul Integr Comp Physiol. 2017 Jun 1;312(6):R903-R911. doi: 10.1152/ajpregu.00064.2017. Epub 2017 Mar 22.

19.

Effect of renal denervation on kidney function in patients with chronic kidney disease.

Hering D, Marusic P, Duval J, Sata Y, Head GA, Denton KM, Burrows S, Walton AS, Esler MD, Schlaich MP.

Int J Cardiol. 2017 Apr 1;232:93-97. doi: 10.1016/j.ijcard.2017.01.047. Epub 2017 Jan 6.

PMID:
28089459
20.

Renal Denervation Reduces Monocyte Activation and Monocyte-Platelet Aggregate Formation: An Anti-Inflammatory Effect Relevant for Cardiovascular Risk.

Zaldivia MT, Rivera J, Hering D, Marusic P, Sata Y, Lim B, Eikelis N, Lee R, Lambert GW, Esler MD, Htun NM, Duval J, Hammond L, Eisenhardt SU, Flierl U, Schlaich MP, Peter K.

Hypertension. 2017 Feb;69(2):323-331. doi: 10.1161/HYPERTENSIONAHA.116.08373. Epub 2016 Dec 12.

PMID:
27956575
21.

Norepinephrine transporter expression is inversely associated with glycaemic indices: a pilot study in metabolically diverse persons with overweight and obesity.

Straznicky NE, Guo L, Corcoran SJ, Esler MD, Phillips SE, Sari CI, Grima MT, Karapanagiotidis S, Wong CY, Eikelis N, Mariani JA, Kobayashi D, Dixon JB, Lambert GW, Lambert EA.

Obes Sci Pract. 2016 Mar;2(1):13-23. Epub 2016 Jan 19.

22.

Reply: Platelet noradrenaline uptake is unrelated to renal denervation.

Barber-Chamoux N, Esler MD.

Nat Rev Cardiol. 2016 Nov;13(11):694. doi: 10.1038/nrcardio.2016.144. Epub 2016 Sep 22. No abstract available.

PMID:
27654390
23.

Soluble vascular endothelial growth factor receptor-1 is reduced in patients with resistant hypertension after renal denervation.

Eikelis N, Hering D, Marusic P, Walton AS, Lambert EA, Sata Y, Krum H, Lambert GW, Esler MD, Schlaich MP.

J Hum Hypertens. 2017 Apr;31(4):248-252. doi: 10.1038/jhh.2016.64. Epub 2016 Sep 8.

PMID:
27604660
24.

A polymorphism in the norepinephrine transporter gene is associated with affective and cardiovascular disease through a microRNA mechanism.

Marques FZ, Eikelis N, Bayles RG, Lambert EA, Straznicky NE, Hering D, Esler MD, Head GA, Barton DA, Schlaich MP, Lambert GW.

Mol Psychiatry. 2017 Jan;22(1):134-141. doi: 10.1038/mp.2016.40. Epub 2016 Apr 5.

PMID:
27046647
25.

Renal artery anatomy affects the blood pressure response to renal denervation in patients with resistant hypertension.

Hering D, Marusic P, Walton AS, Duval J, Lee R, Sata Y, Krum H, Lambert E, Peter K, Head G, Lambert G, Esler MD, Schlaich MP.

Int J Cardiol. 2016 Jan 1;202:388-93. doi: 10.1016/j.ijcard.2015.09.015. Epub 2015 Sep 21.

PMID:
26432488
26.

Health-related quality of life and blood pressure 12 months after renal denervation.

Lambert GW, Hering D, Marusic P, Thorp A, Sata Y, Lee R, Duval J, Hammond L, Head GA, Esler MD, Lambert EA, Dixon JB, Dhar AK, Barton DA, Schlaich MP.

J Hypertens. 2015 Nov;33(11):2350-8. doi: 10.1097/HJH.0000000000000698.

PMID:
26259120
27.

Estimated Added Benefit Of Catheter-Based Renal Denervation For Moderate Treatment-Resistant Hypertension: Impact Of Age And Cardiovascular Risk Factors.

Pietzsch JB, Geisler BP, Esler MD.

Value Health. 2014 Nov;17(7):A474. doi: 10.1016/j.jval.2014.08.1354. Epub 2014 Oct 26. No abstract available.

28.

Rebuttal from Markus P. Schlaich, Yusuke Sata and Murray D. Esler.

Schlaich MP, Sata Y, Esler MD.

J Physiol. 2014 Sep 15;592(18):3947. doi: 10.1113/jphysiol.2014.279729. No abstract available.

29.

CrossTalk opposing view: Which technique for controlling resistant hypertension? Renal nerve ablation.

Schlaich MP, Sata Y, Esler MD.

J Physiol. 2014 Sep 15;592(18):3937-40. doi: 10.1113/jphysiol.2014.270710. No abstract available.

30.

Cognitive function, health-related quality of life, and symptoms of depression and anxiety sensitivity are impaired in patients with the postural orthostatic tachycardia syndrome (POTS).

Anderson JW, Lambert EA, Sari CI, Dawood T, Esler MD, Vaddadi G, Lambert GW.

Front Physiol. 2014 Jun 25;5:230. doi: 10.3389/fphys.2014.00230. eCollection 2014.

31.

Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial.

Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, Mahfoud F, Schlaich MP.

Eur Heart J. 2014 Jul;35(26):1752-9. doi: 10.1093/eurheartj/ehu209. Epub 2014 Jun 4.

32.

Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension.

Hering D, Marusic P, Walton AS, Lambert EA, Krum H, Narkiewicz K, Lambert GW, Esler MD, Schlaich MP.

Hypertension. 2014 Jul;64(1):118-24. doi: 10.1161/HYPERTENSIONAHA.113.03098. Epub 2014 Apr 14.

PMID:
24732891
33.

Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial.

Mahfoud F, Urban D, Teller D, Linz D, Stawowy P, Hassel JH, Fries P, Dreysse S, Wellnhofer E, Schneider G, Buecker A, Schneeweis C, Doltra A, Schlaich MP, Esler MD, Fleck E, Böhm M, Kelle S.

Eur Heart J. 2014 Sep 1;35(33):2224-31b. doi: 10.1093/eurheartj/ehu093. Epub 2014 Mar 6.

PMID:
24603307
34.

Baroreflex sensitivity: a reliable predictor of response to renal denervation?

Hering D, Esler MD, Schlaich MP.

J Am Coll Cardiol. 2014 Jul 15;64(2):232-3. doi: 10.1016/j.jacc.2013.10.088. Epub 2014 Feb 5. No abstract available.

35.

Targeting the sympathetic nervous system: critical issues in patient selection, efficacy, and safety of renal denervation.

Schlaich MP, Esler MD, Fink GD, Osborn JW, Euler DE.

Hypertension. 2014 Mar;63(3):426-32. doi: 10.1161/HYPERTENSIONAHA.113.02144. Epub 2013 Dec 9. Review. No abstract available.

PMID:
24324047
36.

Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study.

Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD.

Lancet. 2014 Feb 15;383(9917):622-9. doi: 10.1016/S0140-6736(13)62192-3. Epub 2013 Nov 7. Erratum in: Lancet. 2014 Feb 15;383(9917):602. Sobotka, Paul A [added].

PMID:
24210779
37.

Association of vitamin D status and blood pressure response after renal denervation.

Pöss J, Mahfoud F, Ukena C, Esler MD, Schlaich M, Hering D, Cremers B, Laufs U, Böhm M.

Clin Res Cardiol. 2014 Jan;103(1):41-7. doi: 10.1007/s00392-013-0621-y. Epub 2013 Oct 31.

PMID:
24173883
38.

International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension.

Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Böhm M, Campese VM, Francis DP, Grassi G, Hering D, Katholi R, Kjeldsen S, Krum H, Mahfoud F, Mancia G, Messerli FH, Narkiewicz K, Parati G, Rocha-Singh KJ, Ruilope LM, Rump LC, Sica DA, Sobotka PA, Tsioufis C, Vonend O, Weber MA, Williams B, Zeller T, Esler MD.

J Am Coll Cardiol. 2013 Dec 3;62(22):2031-45. doi: 10.1016/j.jacc.2013.08.1616. Epub 2013 Sep 18.

39.

Renal denervation: current implications and future perspectives.

Xu J, Hering D, Sata Y, Walton A, Krum H, Esler MD, Schlaich MP.

Clin Sci (Lond). 2014 Jan 1;126(1):41-53. doi: 10.1042/CS20120581. Review.

PMID:
24020446
40.

The effects of dietary weight loss on indices of norepinephrine turnover: modulatory influence of hyperinsulinemia.

Straznicky NE, Lambert EA, Grima MT, Eikelis N, Richards K, Nestel PJ, Dawood T, Masuo K, Sari CI, Dixon JB, Esler MD, Paul E, Schlaich MP, Lambert GW.

Obesity (Silver Spring). 2014 Mar;22(3):652-62. doi: 10.1002/oby.20614. Epub 2013 Dec 6.

41.

Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation.

Hering D, Esler MD, Schlaich MP.

EuroIntervention. 2013 May;9 Suppl R:R127-35. doi: 10.4244/EIJV9SRA22. Review.

PMID:
23732145
42.

Renal nerve ablation reduces augmentation index in patients with resistant hypertension.

Hering D, Lambert EA, Marusic P, Ika-Sari C, Walton AS, Krum H, Sobotka PA, Mahfoud F, Böhm M, Lambert GW, Esler MD, Schlaich MP.

J Hypertens. 2013 Sep;31(9):1893-900. doi: 10.1097/HJH.0b013e3283622e58.

PMID:
23697964
43.

Response to quality of life after renal denervation.

Lambert GW, Hering D, Esler MD, Marusic P, Lambert EA, Tanamas SK, Shaw J, Krum H, Dixon JB, Barton DA, Schlaich MP.

Hypertension. 2013 Apr;61(4):e39. No abstract available.

PMID:
23607138
44.

Cardiac ablation and renal denervation systems have distinct purposes and different technical requirements.

Blessing E, Esler MD, Francis DP, Schmieder RE.

JACC Cardiovasc Interv. 2013 Mar;6(3):314. doi: 10.1016/j.jcin.2012.12.005. No abstract available.

45.

Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease.

Schlaich MP, Bart B, Hering D, Walton A, Marusic P, Mahfoud F, Böhm M, Lambert EA, Krum H, Sobotka PA, Schmieder RE, Ika-Sari C, Eikelis N, Straznicky N, Lambert GW, Esler MD.

Int J Cardiol. 2013 Oct 3;168(3):2214-20. doi: 10.1016/j.ijcard.2013.01.218. Epub 2013 Feb 28.

PMID:
23453868
46.

Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial.

Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA; Symplicity HTN-2 Investigators.

Circulation. 2012 Dec 18;126(25):2976-82. doi: 10.1161/CIRCULATIONAHA.112.130880.

PMID:
23248063
47.

Effects of renal denervation on insulin resistance.

Hering D, Esler MD, Schlaich MP.

Expert Rev Cardiovasc Ther. 2012 Nov;10(11):1381-6. doi: 10.1586/erc.12.140. Review.

PMID:
23244359
48.

Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension.

Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP.

Hypertension. 2013 Feb;61(2):457-64. doi: 10.1161/HYPERTENSIONAHA.111.00194. Epub 2012 Nov 19.

PMID:
23172929
49.

Health-related quality of life after renal denervation in patients with treatment-resistant hypertension.

Lambert GW, Hering D, Esler MD, Marusic P, Lambert EA, Tanamas SK, Shaw J, Krum H, Dixon JB, Barton DA, Schlaich MP.

Hypertension. 2012 Dec;60(6):1479-84. doi: 10.1161/HYPERTENSIONAHA.112.200865. Epub 2012 Oct 15.

PMID:
23071129
50.

Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension.

Geisler BP, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, Pietzsch JB.

J Am Coll Cardiol. 2012 Oct 2;60(14):1271-7. doi: 10.1016/j.jacc.2012.07.029. Epub 2012 Sep 12.

Supplemental Content

Loading ...
Support Center